KraneShares MSCI All China Health Care Index ETF (KURE)
| Assets | $112.24M |
| Expense Ratio | 0.65% |
| PE Ratio | 23.43 |
| Shares Out | 5.85M |
| Dividend (ttm) | $0.71 |
| Dividend Yield | 3.76% |
| Ex-Dividend Date | Dec 22, 2025 |
| Payout Frequency | Annual |
| Payout Ratio | 91.21% |
| Volume | 141,678 |
| Open | 19.33 |
| Previous Close | 19.34 |
| Day's Range | 18.98 - 19.33 |
| 52-Week Low | 14.38 |
| 52-Week High | 21.50 |
| Beta | 0.19 |
| Holdings | 46 |
| Inception Date | Feb 1, 2018 |
About KURE
Fund Home PageThe KraneShares MSCI All China Health Care Index ETF (KURE) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market cap-weighted index of large- and mid-cap Chinese stocks in the health care sector. KURE was launched on Feb 1, 2018 and is issued by KraneShares.
Top 10 Holdings
55.20% of assets| Name | Symbol | Weight |
|---|---|---|
| Innovent Biologics, Inc. | 1801 | 9.04% |
| BeOne Medicines AG | 6160 | 8.60% |
| WuXi Biologics (Cayman) Inc. | 2269 | 7.70% |
| WuXi AppTec Co., Ltd. | 603259 | 5.89% |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 600276 | 4.40% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | 300760 | 4.34% |
| Akeso, Inc. | 9926 | 4.32% |
| Sino Biopharmaceutical Limited | 1177 | 3.92% |
| CSPC Pharmaceutical Group Limited | 1093 | 3.64% |
| Genscript Biotech Corporation | 1548 | 3.37% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 22, 2025 | $0.71469 | Dec 23, 2025 |
| Dec 17, 2024 | $0.18361 | Dec 18, 2024 |
| Dec 18, 2023 | $0.11284 | Dec 20, 2023 |
| Dec 28, 2022 | $0.0104 | Dec 30, 2022 |
| Dec 29, 2021 | $4.05354 | Dec 31, 2021 |
| Dec 29, 2020 | $0.00011 | Dec 31, 2020 |
Performance
KURE had a total return of -5.16% in the past year, including dividends. Since the fund's inception, the average annual return has been -0.72%.
News
Best Pharmaceutical ETFs for Q2 2021
The best pharmaceutical ETFs for Q2 2021 are KURE, MJJ, and POTX.
China Continues to Be Risky for Investors. What to Expect in 2021.
China risks are on multiple fronts—from the technology rivalry with the U.S. to more regulatory scrutiny inside China of internet giants.
Best Healthcare ETFs for Q1 2021
The best healthcare ETFs for Q1 2021 are ARKG, PTH, and KURE.
The Tell: China's bouncing back, but don't bet on other emerging markets to join the ride
China's economy is bouncing back, but other emerging markets aren't likely to enjoy the spoils, says one economist.